Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Fantasy Pharmaceutical Investment Management Co., Ltd. (abbreviated as Fantasy Pharmaceutical) is a pharmaceutical manufacturing holding investment company specializing in the research and development, production, and sales of anti-tumor, cardiovascular, cough relieving, pediatric medication, and antifungal drugs. The company is listed on the A and B shares of the Shanghai Stock Exchange (stock code: A share: 600613; B share: 900904). The company's "Magic" brand has a business history of over 30 years. In 2002, it was rated as a "well-known trademark in China" by the State Administration for Industry and Commerce. From 2004 to 2014, it has been listed as one of the top 500 most valuable brands in China by the World Brand Laboratory for 11 consecutive years. On January 12, 2015, Magic Pharmaceuticals was crowned as one of the "2015 Forbes China Top 100 Listing Potential Enterprises". From 2012 to 2018, it has been awarded the most influential "Made in China Top 100" and "Top 50 Growth Enterprises in the Chinese Pharmaceutical Industry" for seven consecutive years. The company has formed a brand culture, brand awareness, reputation, and influence of "Magic Chinese Medicine, Valuable in Efficacy" throughout the country. Magic Pharmaceutical currently has 11 production bases in Guiyang, Longli, Duyun, and Luodian, covering a total area of over 1000 acres. It has more than 10 dosage forms and 37 production lines, all of which have passed national compliance inspections. Magic Pharmaceutical is investing in the construction of a new factory area in Guiyang High tech Development Zone, covering an area of 300 acres. Magic Pharmaceuticals will strive to build the new factory area into a modern pharmaceutical technology industrial park that is efficient, environmentally friendly, people-oriented, and sustainable. Magic Pharmaceuticals adheres to the mission of "providing high-quality products and services for public health through continuous innovation", and always adheres to the enterprise production quality policy of "quality is the god, and the therapeutic effect is remarkable"; At the same time, the company has also established long-term cooperative relationships with renowned drug research institutions both domestically and internationally. It has now developed 14 independent intellectual property rights of ethnic medicines and dozens of national invention patents. The company's research and technological innovation capabilities have been recognized by society. The company's products combine prescription drugs and OTC varieties, mainly selling products in eight major fields, including anti-tumor series, cardiovascular and cerebrovascular series, cough and cold series, magical doll children's series, antifungal series, and tonifying products. It has 141 national drug approved brand products and is sold in more than 100 prefecture level cities in 31 provinces (cities, autonomous regions) nationwide. While developing and growing, Magic Pharmaceuticals always maintains a strong sense of social responsibility and never forgets to repay society. We have donated over 200 million yuan to pave roads and bridges in Guizhou, provide targeted assistance to farmers in poverty-stricken areas for development, and build primary and secondary schools. We have also funded the establishment of "impoverished student scholarships" at Beijing University of Traditional Chinese Medicine, Shenyang Pharmaceutical University, and Guizhou University for Nationalities to help impoverished students complete their studies. In March 2002, the "Guangcai Rehabilitation Project" was implemented, and through the Ministry of Health of the People's Republic of China, an anti tuberculosis drug of 120 million yuan (formerly known as Tuberculosis Kangxin Tablets) was provided free of charge to 12 impoverished counties in Africa and western regions. In 2020, it won the title of "China's Most Influential Anti epidemic Charity Enterprise" during the fight against the "COVID-19" epidemic. |
| Headquarter | Shanghai |
| Establish Date | 7/22/1992 |
| Listed Code | 600613.SH |
| Listed Date | 8/20/1992 |
| Chairman | ZHANG TAO TAO. |
| CEO | Feng Bin. |
| Website | www.gzsq.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
